TCTR20211122002
Recruiting
Phase 4
An open-label, pilot study evaluating the efficacy of a lip balm containing panthenol and bisabolol as a monotherapy for the treatment of mild to moderate cheilitis
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand0 sites20 target enrollmentNovember 22, 2021
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Patients diagnosed with mild to moderate cheilitis
- Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Aged 18 years or older
- •2\. Patients who were diagnosed with mild to moderate cheilitis by dermatologists
Exclusion Criteria
- •(i) patients with other dermatologic diseases of the lips, (ii) patients with a history of contact allergy to panthenol and bisabolol, (iii) patients applied topical corticosteroids or topical calcineurin inhibitors at the lips 1 week prior to inclusion, (iv) patients taking oral corticosteroids 2 weeks prior to enrollment, and/or (v) pregnant or lactating patients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An open label pilot study to evaluate the efficacy and safety of topical tacrolimus 0l1% (Protopic) in the treatment of varicose eczemaEUCTR2004-004467-29-GBCraigavon Area Hospital Group Trust12
Recruiting
Phase 1
An open-label pilot trial of N-acetyl cysteine treatment for body dysmorphic disorderBody dysmorphic disorderMental Health - Other mental health disordersACTRN12616001546448St Vincent's Hospital Melbourne20
Active, not recruiting
Phase 1
A Phase 2, open-label study to assess the efficacy and safety of AK002 in patients with chronic urticaria who do not respond to anithistaminesPatients with different types of chronic urticaria resistant to standard dose antihistaminesMedDRA version: 20.0Level: PTClassification code 10052568Term: Urticaria chronicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2017-002581-51-DEAllakos Inc.48
Active, not recruiting
Phase 1
A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS)Schnitzler’s syndrome (SchS)MedDRA version: 19.1 Level: PT Classification code 10062908 Term: Schnitzler's syndrome System Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2016-003828-23-DECharité - Universitätsmedizin Berlin; Dpt. of Dermatology and Allergy12
Recruiting
Phase 1
Clinical study to assess the efficacy and safety of Cannabidiol in children and young adults with rare disease-associated severe epilepsyEpilepsyMedDRA version: 21.0Level: PTClassification code: 10015037Term: Epilepsy Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]CTIS2023-503709-12-00Azienda Ospedaliero Universitaria Meyer IRCCS30